v3.25.1
Convertible Preferred Stock and Stockholders’ Equity (Tables)
3 Months Ended
Mar. 31, 2025
Convertible Preferred Stock and Stockholders’ Equity [Abstract]  
Schedule of Outstanding Warrants

The following summarizes the Company’s outstanding warrants, excluding contingent warrants issuable upon exercise of the outstanding warrants as of March 31, 2025:

 

   Number of
Shares
   WA
Average
Exercise
Price
   WA
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2024   1,175,333   $6.72    2.92 
Granted   
    
     
Exercised   
    
     
Cancelled   
    
     
Outstanding as of March 31, 2025   1,175,333    6.72    2.67 
Warrants vested and exercisable as of March 31, 2025   583,475   $9.10    2.33 
Schedule of Stock Options

The following summarizes activity related to the Company’s stock options under the 2019 Plan and the 2022 Plan for the three months ended March 31, 2025:

 

           Weighted 
           Average 
       Weighted   Remaining 
       Average   Contractual 
   Number of   Exercise   Life 
   Shares   Price   (in years) 
Outstanding as of December 31, 2024   13,674   $156.96    7.9 
Granted   
    
     
Forfeited / cancelled   
    
     
Exercised   
    
     
Outstanding as of March 31, 2025   13,674    156.96    7.7 
Options vested and exercisable as of March 31, 2025   9,982   $184.47    7.5 
Schedule of Restricted Stock

The following summarizes activity related to the Company’s restricted stock awards granted under the 2022 Plan for the three months ended March 31, 2025:

 

       Weighted 
       Average 
   Number of   Grant Date 
   Shares   Fair Value 
Nonvested as of December 31, 2024   17,917   $6.15 
Granted   1,709    0.42 
Vested   
    
 
Forfeited   
    
 
Nonvested as of March 31, 2025   19,626   $6.80 
Schedule of Stock-Based Compensation Expense

Stock-based compensation expense related to stock options and restricted stock, for the three months ended March 31, 2025 and 2024 was as follows:

 

   For the Three Months Ended
March 31,
 
   2025   2024 
Selling, general and administrative  $29,256   $51,184 
Research and development   
    1,466 
Total  $29,256   $52,650